Connectez-vous pour enregistrer et recevoir des mises à jour.
L'émergence de la Chine en tant qu'innovatrice mondiale dans le secteur pharmaceutique (les incitations comptent)
This paper examines China’s transition from pharmaceutical “free rider” to global innovator over the last decade. In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume. To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug […] The post The rise of China as a global innovator in pharma (incentives matter) appeared first on Marginal REVOLUTION. Re...
Articles sources
Marginal Revolution (United States) | Mar 24, 2026
Your votes count
No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.
Traduit par IA · Voir l'original
While China's growth in the pharma sector is notable, it raises concerns about ethical practices and regulatory oversight in drug development.
Traduit par IA · Voir l'original
China's rise as a pharmaceutical innovator is a positive development, as it enhances global competition and drives down drug prices.
Traduit par IA · Voir l'original
The shift in clinical trial volume to China reflects broader trends in globalization and should be seen as a natural evolution in the pharma industry.
Traduit par IA · Voir l'original
China's rapid advancement in pharma poses risks of intellectual property theft and undermines established global standards in drug safety.
Traduit par IA · Voir l'original
China's transition to a global innovator in pharmaceuticals could lead to better healthcare outcomes worldwide, benefiting populations everywhere.
💡 How This Works
- • Add Statements: Post claims or questions (10-500 characters)
- • Vote: Agree, Disagree, or Unsure on each statement
- • Respond: Add detailed pro/con responses with evidence
- • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement
Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.
Support us